Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: APP009
MIFTS: 43

Appendix Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Appendix Adenocarcinoma

About this section

MalaCards integrated aliases for Appendix Adenocarcinoma:

Name: Appendix Adenocarcinoma 12 15 17
Mucinous Adenocarcinoma 54 74
Cystadenocarcinoma 54 74
Adenocarcinoma of the Appendix 54
Colonic Type Adenocarcinoma 54
Appendiceal Adenocarcinoma 12
Nonmucinous Adenocarcinoma 54
Adenocarcinoma of Appendix 74

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3608
NCIt 51 C7718
Sources

Summaries for Appendix Adenocarcinoma

About this section
NIH Rare Diseases : 54 Cancer of the appendix is very rare and is typically found incidentally during appendectomies, in about 1% of the cases. According to a report published by the National Cancer Institute, using the Surveillance, Epidemiology, and End Results (SEER) database, appendix cancer account for about 0.4% of gastrointestinal tumors. There are several subytpes. The most common is the carcinoid type (66% of the total), with cyst-adenocarcinoma accounting for 20% and adenocarcinoma accounting for 10%. Then there are the rare forms of cancers which include adenocarcinoid, signet ring, non-Hodgkin�??s lymphoma, ganglioneuroma, and pheochromocytoma. Benign primary tumors are mainly �??mucinous epithelial neoplasms�?�, also called adenomas, cystadenoma, and benign neoplastic mucocele.Adenocarcinoma of the appendix is a epithelial cancer of the appendix. The term 'epithelium' refers to cells that line hollow organs and glands and those that make up the outer surface of the body. Epithelial cells help to protect or enclose organs. Some produce mucus or other secretions. Types of adenocarcinoma of the appendix include mucinous adenocarcinoma, non-mucinous adenocarcinoma, and signet cell carcinoma of the appendix (which is the rarest, involving only 4% of all the subtypes of appendix cancer).

MalaCards based summary : Appendix Adenocarcinoma, also known as mucinous adenocarcinoma, is related to mucinous cystadenocarcinoma and bile duct cystadenocarcinoma. An important gene associated with Appendix Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways is Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Bevacizumab and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include appendix, colon and lung.

Disease Ontology : 12 An appendix carcinoma that derives from epithelial cells of glandular origin.

Sources

Related Diseases for Appendix Adenocarcinoma

About this section

Diseases related to Appendix Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 315)
# Related Disease Score Top Affiliating Genes
1 mucinous cystadenocarcinoma 33.9 KRT20 KRT7
2 bile duct cystadenocarcinoma 33.5 KRT20 KRT7
3 mucinous adenocarcinoma 33.4 CDX2 KRT20 KRT7
4 ovarian mucinous adenocarcinoma 33.3 CDX2 KRT20 KRT7
5 pseudomyxoma peritonei 32.1 CDX2 KRT20 KRT7
6 papillary serous adenocarcinoma 31.6 KRT20 KRT7
7 teratoma 30.8 CDX2 KRT7
8 villous adenoma 30.4 CDX2 KRT20
9 krukenberg carcinoma 30.2 KRT20 KRT7
10 anal canal adenocarcinoma 30.2 CDX2 KRT7
11 cervical adenocarcinoma 30.1 CDX2 KRT20 KRT7
12 cystic teratoma 30.1 CDX2 KRT20 KRT7
13 large cell neuroendocrine carcinoma 30.0 KRT20 KRT7
14 thymus adenocarcinoma 30.0 CDX2 KRT20 KRT7
15 vulva adenocarcinoma 30.0 CDX2 KRT20 KRT7
16 mammary paget's disease 29.9 KRT20 KRT7
17 mucinous ovarian cystadenoma 29.8 CDX2 KRT7
18 clear cell adenocarcinoma 29.8 KRT20 KRT7
19 transverse colon cancer 29.8 KRT20 KRT7
20 small cell carcinoma 29.8 KRT20 KRT7
21 eyelid carcinoma 29.8 KRT20 KRT7
22 adenocarcinoma in situ 29.8 CDX2 KRT20 KRT7
23 cystadenoma 29.7 KRT20 KRT7
24 dermoid cyst 29.7 KRT20 KRT7
25 cholangiocarcinoma 29.6 CDX2 KRT20 KRT7
26 pancreatic ductal carcinoma 29.6 KRT20 KRT7
27 polycystic liver disease 1 with or without kidney cysts 29.6 KRT20 KRT7
28 signet ring cell adenocarcinoma 29.6 CDX2 KRT20 KRT7
29 sweat gland cancer 29.5 KRT20 KRT7
30 transitional cell carcinoma 29.4 KRT20 KRT7
31 endocervical adenocarcinoma 29.4 CDX2 KRT20 KRT7
32 ovarian mucinous neoplasm 29.4 CDX2 KRT20 KRT7
33 intrahepatic cholangiocarcinoma 29.4 CDX2 KRT20 KRT7
34 horseshoe kidney 29.4 CDX2 KRT20 KRT7
35 bronchiolo-alveolar adenocarcinoma 29.4 CDX2 KRT20 KRT7
36 intestinal obstruction 29.4 CDX2 KRT20 KRT7
37 colorectal adenocarcinoma 29.4 CDX2 KRT20 KRT7
38 gastric adenocarcinoma 29.2 CDX2 KRT20 KRT7
39 lung cancer susceptibility 3 29.2 CDX2 KRT20 KRT7
40 appendix cancer 28.7 CDX2 KRT20 KRT7 RHCE
41 serous cystadenocarcinoma 12.6
42 papillary cystadenocarcinoma 12.5
43 ovarian mucinous cystadenocarcinoma 12.5
44 pancreatic serous cystadenocarcinoma 12.5
45 villoglandular variant cervical mucinous adenocarcinoma 12.4
46 signet ring cell variant cervical mucinous adenocarcinoma 12.4
47 intestinal variant cervical mucinous adenocarcinoma 12.4
48 colon mucinous adenocarcinoma 12.4
49 endometrial mucinous adenocarcinoma 12.4
50 mucinous adenocarcinoma of ovary 12.4

Graphical network of the top 20 diseases related to Appendix Adenocarcinoma:



Diseases related to Appendix Adenocarcinoma
Sources

Symptoms & Phenotypes for Appendix Adenocarcinoma

About this section
Sources

Drugs & Therapeutics for Appendix Adenocarcinoma

About this section

Drugs for Appendix Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 246)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
4
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
7
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
8
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
11
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 5284616 6436030
14
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
15
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
16
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 70789204 6442177
17
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
18
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
19
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
20
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
21
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
22
Olaparib Approved Phase 2, Phase 3,Phase 1,Early Phase 1 763113-22-0 23725625
23
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
24
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
25
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
26
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
27
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
28
Sodium Citrate Approved, Investigational Phase 2, Phase 3 68-04-2
29
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
30
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
31
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 7440-70-2 271
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
33
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
35
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
36 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
37
Camptothecin Experimental Phase 3 7689-03-4
38
Maleic acid Experimental, Investigational Phase 2, Phase 3,Phase 1 110-17-8, 110-16-7 444972
39
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
40 Paclitaxel poliglumex Experimental, Investigational Phase 3,Phase 1 263351-82-2
41 Antimetabolites Phase 3,Phase 2,Phase 1
42 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
44 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
45 Calcium, Dietary Phase 3,Phase 2,Phase 1,Early Phase 1
46 Alkylating Agents Phase 3,Phase 2,Phase 1
47 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
48 Antidotes Phase 3,Phase 2,Phase 1
49 Folate Phase 3,Phase 2,Phase 1,Not Applicable
50 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 220)
# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
4 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
8 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
11 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
12 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
13 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
16 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
17 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
18 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
19 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
20 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
21 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
22 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
23 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
24 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
25 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
26 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
27 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
28 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
29 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Not yet recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
30 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
31 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
32 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
33 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
34 Second Look Laparoscopy in Colorectal Cancer Unknown status NCT01628211 Phase 2 Folinic Acid;5-Fluorouracil;Oxaliplatin;systemic chemotherapy
35 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
36 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
37 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
38 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
39 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
40 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
41 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
42 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
43 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
44 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
45 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
46 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
47 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
48 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
49 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
50 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel

Search NIH Clinical Center for Appendix Adenocarcinoma

Sources

Genetic Tests for Appendix Adenocarcinoma

About this section
Sources

Anatomical Context for Appendix Adenocarcinoma

About this section

MalaCards organs/tissues related to Appendix Adenocarcinoma:

42
Appendix, Colon, Lung, Ovary, Liver, Breast, Prostate
Sources

Publications for Appendix Adenocarcinoma

About this section

Articles related to Appendix Adenocarcinoma:

(show top 50) (show all 650)
# Title Authors Year
1
Diffuse calcificated infiltrations of the intrahepatic bile duct: Metastasis of mucinous adenocarcinoma. ( 31079838 )
2019
2
Mucinous adenocarcinoma of the rectum with uninjured mucosa. ( 31081269 )
2019
3
Signet ring cell component predicts aggressive behaviour in colorectal mucinous adenocarcinoma. ( 31029443 )
2019
4
Mucinous adenocarcinoma of the abdomen. ( 30900376 )
2019
5
Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report. ( 30841908 )
2019
6
Malignant melanoma of the esophagus complicated with poorly differentiated mucinous adenocarcinoma of the stomach: A case report. ( 30855489 )
2019
7
Solitary Nodular Invasive Mucinous Adenocarcinoma of the Lung: Imaging Diagnosis Using the Morphologic-Metabolic Dissociation Sign. ( 30799583 )
2019
8
Clinicopathological characteristics of patients with mucinous adenocarcinoma of the uterine cervix: A retrospective study of 21 cases. ( 30807852 )
2019
9
MRI features of mucinous adenocarcinoma of the prostate: report of four cases. ( 30810795 )
2019
10
Primary Mucinous Adenocarcinoma of Skin in Axilla: A Case Report and Review of Literature. ( 30745645 )
2019
11
Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report. ( 30792968 )
2019
12
Ciliated muconodular papillary tumour of the lung mimicking mucinous adenocarcinoma: a case report and literature review. ( 30713144 )
2019
13
Mucinous adenocarcinoma of the endometrium with metastasis to the clitoral glans after pelvic exenteration for radiation resistant vaginal cuff recurrence. ( 30627614 )
2019
14
A Novel CAMKMT Exon3-ALK Exon20 Fusion Variant was Identified in a Primary Pulmonary Mucinous Adenocarcinoma. ( 30579547 )
2019
15
A rare case of incidental mucinous adenocarcinoma with osseous metaplasia associated with cysts of the presacral space. ( 30460902 )
2019
16
Mucinous adenocarcinoma of gallbladder: Subcategorisation on fine-needle aspiration cytology. ( 30375181 )
2019
17
Anaplastic Carcinoma Arising From Ovarian Mucinous Adenocarcinoma With Massive Cardiopulmonary Metastasis: An Autopsy Case Report. ( 30393058 )
2019
18
Can Quantitative Volumetric Analysis Predict Tumor Recurrence in the Patients with Mucinous Adenocarcinoma of the Lung After Surgical Resection? ( 30064921 )
2019
19
Non-human Papillomavirus Cervical Mucinous Adenocarcinoma in a Phenotypic Male with Congenital Adrenal Hyperplasia. ( 30680268 )
2018
20
Invasive Mucinous Adenocarcinoma in Congenital Pulmonary Airway Malformation: A Case Report. ( 30595422 )
2018
21
hCG production by mucinous adenocarcinoma of the ovary in a reproductive aged woman. ( 30533474 )
2018
22
Trends of incidence and survival in patients with gastrointestinal mucinous adenocarcinoma. ( 30344730 )
2018
23
Multicentric Mucinous Adenocarcinoma in the Periorbital Region. ( 30365480 )
2018
24
Intestinal epithelial Notch-1 protects from colorectal mucinous adenocarcinoma. ( 30323897 )
2018
25
Primary mucinous adenocarcinoma of the eyelid: A case report and literature review. ( 30251739 )
2018
26
Invasive mucinous adenocarcinoma of the lung in a 19-year-old female. ( 30269525 )
2018
27
Incidental discovery of mucinous adenocarcinoma of the prostate following transurethral resection of the prostate: A report of two cases and a literature review. ( 30214732 )
2018
28
Colonic adenosquamous carcinoma and mucinous adenocarcinoma with microsatellite instability. ( 30173239 )
2018
29
Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study. ( 30069357 )
2018
30
Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: A case report and literature review. ( 30101020 )
2018
31
Urachal mucinous adenocarcinoma in the pelvic wall mimicking endometriosis. ( 30108674 )
2018
32
Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma. ( 29983574 )
2018
33
Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. ( 29992451 )
2018
34
Rare Case of Iliopsoas Abscess Secondary to Mucinous Adenocarcinoma of the Colon: A Case Report. ( 29854689 )
2018
35
Mucinous Adenocarcinoma of the Scalp: Primary Cutaneous Neoplasm Versus Underlying Metastatic Disease. ( 29876191 )
2018
36
Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma. ( 29771808 )
2018
37
Laparoscopic abdominoperineal resection for the treatment of a mucinous adenocarcinoma associated with an anal fistula. ( 29593864 )
2018
38
Vulvar Carcinosarcoma Composed of Intestinal-type Mucinous Adenocarcinoma Associated With Anaplastic Pleomorphic and Spindle Cell Carcinoma and Heterologous Chondrosarcomatous and Osteosarcomatous Elements: A Case Report and Review of the Literature. ( 28319579 )
2018
39
Right-colon mucinous adenocarcinoma mimicking a hydatid cyst. ( 29313694 )
2018
40
Mucinous adenocarcinoma of unknown primary presenting with dysphagia. ( 29223385 )
2018
41
Mucinous adenocarcinoma in association with hidradenitis suppurativa: a new example of isoscartopic response. ( 29271499 )
2018
42
Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study. ( 28785968 )
2018
43
Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis. ( 28823574 )
2018
44
Mucinous adenocarcinoma with lepidic pattern and with K-RAS mutation in a newborn with antenatal diagnosis of congenital pulmonary airway malformation. ( 28889407 )
2018
45
Endocrine Mucin-Producing Sweat Gland Carcinoma of the Eyelid Associated With Mucinous Adenocarcinoma. ( 28902090 )
2018
46
Mucinous adenocarcinoma on perianal fistula. A rising entity? ( 28929316 )
2018
47
Pseudomyxoma Peritonei Arising From Urachal Mucinous Adenocarcinoma. ( 29024737 )
2018
48
Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung. ( 29371584 )
2018
49
Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. ( 29375717 )
2018
50
Perianal Paget disease secondary to pagetoid spread of mucinous adenocarcinoma of the anal canal. ( 29400297 )
2018
Sources

Variations for Appendix Adenocarcinoma

About this section

Cosmic variations for Appendix Adenocarcinoma:

9 (show top 50) (show all 362)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6938356 ZFHX3 large intestine,appendix,carcinoma,adenocarcinoma c.3122A>C p.K1041T 16:72950563-72950563 0
2 COSM6933903 XIAP large intestine,appendix,carcinoma,adenocarcinoma c.591A>T p.Q197H 23:123886253-123886253 0
3 COSM6976113 WT1 large intestine,appendix,carcinoma,adenocarcinoma c.463G>A p.D155N 11:32428599-32428599 0
4 COSM44944 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.451C>G p.P151A 17:7675161-7675161 0
5 COSM10883 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.731G>A p.G244D 17:7674232-7674232 0
6 COSM10704 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 0
7 COSM10645 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.527G>T p.C176F 17:7675085-7675085 0
8 COSM10808 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.488A>G p.Y163C 17:7675124-7675124 0
9 COSM11286 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.1015G>T p.E339* 17:7670694-7670694 0
10 COSM10863 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.833C>T p.P278L 17:7673787-7673787 0
11 COSM10659 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.817C>T p.R273C 17:7673803-7673803 0
12 COSM43955 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.514G>A p.V172I 17:7675098-7675098 0
13 COSM10648 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 0
14 COSM10662 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 0
15 COSM10794 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.796G>A p.G266R 17:7673824-7673824 0
16 COSM12193 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.668C>T p.P223L 17:7674863-7674863 0
17 COSM44093 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.644G>A p.S215N 17:7674887-7674887 0
18 COSM43872 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.560-1G>C p.? 17:7674972-7674972 0
19 COSM6901 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.559+1G>A p.? 17:7675052-7675052 0
20 COSM11073 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.1024C>T p.R342* 17:7670685-7670685 0
21 COSM44388 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.853G>T p.E285* 17:7673767-7673767 0
22 COSM11183 TP53 large intestine,appendix,carcinoma,adenocarcinoma c.799C>T p.R267W 17:7673821-7673821 0
23 COSM6954252 TOP1 large intestine,appendix,carcinoma,adenocarcinoma c.1303A>G p.I435V 20:41101348-41101348 0
24 COSM2983542 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1582C>G p.R528G 3:30691477-30691477 0
25 COSM33076 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1583G>A p.R528H 3:30691478-30691478 0
26 COSM6938933 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.1069G>T p.G357W 3:30672252-30672252 0
27 COSM6503127 TGFBR2 large intestine,appendix,carcinoma,adenocarcinoma c.155A>C p.K52T 3:30644807-30644807 0
28 COSM6967188 TCF7L2 large intestine,appendix,carcinoma,adenocarcinoma c.1760C>T p.P587L 10:113165941-113165941 0
29 COSM6083762 STK11 large intestine,appendix,carcinoma,adenocarcinoma c.752G>T p.G251V 19:1221230-1221230 0
30 COSM6932862 STAT3 large intestine,appendix,carcinoma,adenocarcinoma c.365C>T p.A122V 17:42345566-42345566 0
31 COSM6938938 SPOP large intestine,appendix,carcinoma,adenocarcinoma c.413G>A p.R138H 17:49619048-49619048 0
32 COSM4067486 SPOP large intestine,appendix,carcinoma,adenocarcinoma c.295C>T p.R99W 17:49619291-49619291 0
33 COSM6982254 SOX9 large intestine,appendix,carcinoma,adenocarcinoma c.613A>T p.K205* 17:72122900-72122900 0
34 COSM2719086 SOX17 large intestine,appendix,carcinoma,adenocarcinoma c.329C>T p.T110M 8:54459079-54459079 0
35 COSM4596765 SMARCB1 large intestine,appendix,carcinoma,adenocarcinoma c.1130G>T p.R377L 22:23834152-23834152 0
36 COSM3724529 SMARCA4 large intestine,appendix,carcinoma,adenocarcinoma c.2438+1G>A p.? 19:11013113-11013113 0
37 COSM14151 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1081C>A p.R361S 18:51065548-51065548 0
38 COSM14096 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1333C>T p.R445* 18:51076662-51076662 0
39 COSM14134 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1576G>T p.E526* 18:51078384-51078384 0
40 COSM14122 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1082G>A p.R361H 18:51065549-51065549 0
41 COSM6963798 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1607T>C p.L536P 18:51078415-51078415 0
42 COSM14050 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1516G>A p.V506M 18:51078324-51078324 0
43 COSM6972560 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.424+1G>T p.? 18:51048861-51048861 0
44 COSM14049 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1067C>T p.P356L 18:51065534-51065534 0
45 COSM6053946 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.413C>G p.S138* 18:51048849-51048849 0
46 COSM6983349 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1528G>T p.G510* 18:51078336-51078336 0
47 COSM6976714 SMAD4 large intestine,appendix,carcinoma,adenocarcinoma c.1207A>T p.S403C 18:51067086-51067086 0
48 COSM6983347 SMAD3 large intestine,appendix,carcinoma,adenocarcinoma c.809G>T p.C270F 15:67181391-67181391 0
49 COSM6023609 SMAD3 large intestine,appendix,carcinoma,adenocarcinoma c.269G>T p.R90L 15:67164957-67164957 0
50 COSM3981624 SMAD3 large intestine,appendix,carcinoma,adenocarcinoma c.277C>T p.R93* 15:67164965-67164965 0
Sources

Expression for Appendix Adenocarcinoma

About this section
Search GEO for disease gene expression data for Appendix Adenocarcinoma.
Sources

Pathways for Appendix Adenocarcinoma

About this section

Pathways related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
10.75 ALCAM CDX2
Sources

GO Terms for Appendix Adenocarcinoma

About this section

Biological processes related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 8.62 KRT20 KRT7
Sources

Sources for Appendix Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....